IN THE NEWS
Vical H1 Vaccine on Channel 10 News in San Diego
CLINICAL TRIALS
Click below to learn more about current Vical clinical trials for specific cancer and infectious disease applications.
INVESTOR INFO
| NASDAQ: VICL | |
WELCOME TO VICAL
Vical researches and develops biopharmaceutical products based on our patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases.
VAXFECTIN®
Vical's proprietary Vaxfectin® adjuvant has demonstrated safety and effectiveness in a number of animal models. In July 2008, we announced preliminary clinical trial data demonstrating that Vaxfectin®-formulated DNA vaccines can safely achieve significant immune responses against H5N1 pandemic influenza in humans. References to published data are included in the Vaxfectin® Publications page.